secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2026-08-10T21:13:18+00:00
Accession:  0001193125-26-342667
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz to acquire Actio Biosciences for $820M upfront plus up to $500M in milestones
--------------------------------------------------------------------------------

- Upfront consideration of $820M; contingent milestones up to $500M (ABS-1230 regulatory approval and sales thresholds).
- Milestones: $250M on regulatory approval for ABS-1230 in KCNT1-Related Epilepsy; $100M at $500M annual sales; $150M at $1B annual sales.
- Spin-Out: non-ABS-1230 programs transferred to SpinCo; Jazz retains minority equity stake.
- Closing conditions: HSR clearance, 85% stockholder approval, Spin-Out completion, no termination fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312526342667/0001193125-26-342667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312526342667/d151973d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-342667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer